GW Pharmaceuticals Announces Research & Development – Nasdaq

– Dr. Volker Knappertz appointed Chief Medical Officer –
– Professor Ben Whalley to join as Head of Discovery Research –

LONDON, May 15, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced the appointment of Volker Knappertz, M.D. as Chief Medical Officer (CMO). Reporting to GW’s Chief Executive Officer Justin Gover, Dr. Knappertz will be based in the Company’s U.S. headquarters in Carlsbad, California. In addition, GW has appointed Prof. Ben Whalley as Head of Discovery Research, based in the UK.

“I am delighted to welcome Volker and Ben to GW in these important RD roles,” stated Justin Gover, GW’s Chief Executive Officer. “Volker has an impressive record of successful new drug development and obtaining regulatory approvals which,

... read more at: